CereScape Pty Ltd
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
現在選択しているストアで観測したダウンロード価格です。地域別価格を開くと、国ごとの換算価格を比較できます。
Apple の公開 App Store ページで現在確認できる項目です。App Store Connect の完全な商品一覧とは限りません。
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
最新の App Store 観測データに基づく回答です。
最新の観測ダウンロード価格は 59.000đ です。現在の決済価格は公式 App Store リンクで確認してください。
Apple の公開ページでは現在、このストアで 0 件の購入項目が表示されています。公開一覧は完全ではない場合があります。
はい。App Store の価格はストア、通貨、税、開発者の価格設定によって異なる場合があります。現在 1 地域の観測データがあります。